Evidence map›Paper›PMID 20194335›Full record

ReviewThe Journal of bone and joint surgery. American volume2010

The assessment of fracture risk.

Aasis Unnanuntana, Brian P Gladnick, Eve Donnelly, Joseph M Lane

Abstract readReview
In one paragraph

Review in The Journal of bone and joint surgery. American volume, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
153citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

153 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2013
    Pooled it
  3. Trial
  4. Trial
  5. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018
    Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. The prospective association between high-density lipoprotein (HDL) cholesterol and risk of incident fractures in the general population.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
  13. Article
  14. Review
  15. Review
  16. Bone Health in Space Flight: Incomplete Bone Mineral Density Convalescence at 1 Year Postmission Without Increased Fracture Risk.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2025
    Article
  17. Article
  18. Article
  19. Review
  20. Article

93 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aasis UnnanuntanaDepartment of Orthopaedic Surgery, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA. unnanuntanaa@hss.edu
Brian P Gladnick
Eve Donnelly
Joseph M Lane

Funding

Effects of bone tissue mineral and matrix properties on fracture incidenceF32AR056148 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI DONNELLY, EVE · 2008 to 2010
$154k
NIAMS NIH HHS F32 AR561482
6 · The paper itself

Abstract

Bone mineral density is considered to be the standard measure for the diagnosis of osteoporosis and the assessment of fracture risk. The majority of fragility fractures occur in patients with bone mineral density in the osteopenic range. The Fracture Risk Assessment Tool (FRAX) can be used as an assessment modality for the prediction of fractures on the basis of clinical risk factors, with or without the use of femoral neck bone mineral density. Treatment of osteoporosis should be considered for patients with low bone mineral density (a T-score of between -1.0 and -2.5) as well as a ten-year risk of hip fracture of > or = 3% or a ten-year risk of a major osteoporosis-related fracture of > or = 20% as assessed with the FRAX. Biochemical bone markers are useful for monitoring the efficacy of antiresorptive or anabolic therapy and may aid in identifying patients who have a high risk of fracture. An approach combining the assessment of bone mineral density, clinical risk factors for fracture with use of the FRAX, and bone turnover markers will improve the prediction of fracture risk and enhance the evaluation of patients with osteoporosis.

Indexed as

Bone DensityAbsorptiometry, PhotonFractures, BoneHumansOsteoporosisRisk AssessmentRisk Factors

Identifiers

PMID20194335
PMCPMC2827823

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.